TY - JOUR
T1 - SARS-CoV-2 immunity
T2 - review and applications to phase 3 vaccine candidates
AU - Poland, Gregory A.
AU - Ovsyannikova, Inna G.
AU - Kennedy, Richard B.
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/11/14
Y1 - 2020/11/14
N2 - Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
AB - Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85095440439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095440439&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)32137-1
DO - 10.1016/S0140-6736(20)32137-1
M3 - Review article
C2 - 33065034
AN - SCOPUS:85095440439
SN - 0140-6736
VL - 396
SP - 1595
EP - 1606
JO - The Lancet
JF - The Lancet
IS - 10262
ER -